Analysts Expect Bristol-Myers Squibb (BMY) Will Announce Quarterly Sales of $5.10 Billion
Equities research analysts expect that Bristol-Myers Squibb (NYSE:BMY) will post sales of $5.10 billion for the current quarter, Zacks reports. Three analysts have issued estimates for Bristol-Myers Squibb’s earnings. The lowest sales estimate is $4.93 billion and the highest is $5.24 billion. Bristol-Myers Squibb posted sales of $4.93 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.4%. The business is expected to announce its next earnings report before the market opens on Thursday, April 26th.
According to Zacks, analysts expect that Bristol-Myers Squibb will report full year sales of $21.48 billion for the current financial year, with estimates ranging from $20.86 billion to $21.86 billion. For the next financial year, analysts forecast that the company will post sales of $23.48 billion per share, with estimates ranging from $21.97 billion to $24.58 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 EPS.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in shares of Bristol-Myers Squibb by 108.5% during the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares in the last quarter. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 5.0% during the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after buying an additional 4,945,515 shares in the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 2,990.5% during the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Bristol-Myers Squibb by 42,071.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares in the last quarter. 71.51% of the stock is owned by institutional investors.
Shares of BMY opened at $54.08 on Tuesday. The stock has a market capitalization of $95,750.99, a P/E ratio of 17.97, a P/E/G ratio of 1.52 and a beta of 0.96. Bristol-Myers Squibb has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.96%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.